These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 29359795)
41. Optimization of prophylaxis for hemophilia A. Herbert RD; Broderick CR; Barnes C; Billot L; Zhou A; Latimer J PLoS One; 2018; 13(2):e0192783. PubMed ID: 29447219 [TBL] [Abstract][Full Text] [Related]
42. Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the Unknown. Abdi A; Linari S; Pieri L; Voorberg J; Fijnvandraat K; Castaman G Semin Thromb Hemost; 2018 Sep; 44(6):568-577. PubMed ID: 29439277 [TBL] [Abstract][Full Text] [Related]
43. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis. Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077 [TBL] [Abstract][Full Text] [Related]
44. Non-factor replacement therapy for haemophilia: a current update. Franchini M; Mannucci PM Blood Transfus; 2018 Sep; 16(5):457-461. PubMed ID: 29517971 [TBL] [Abstract][Full Text] [Related]
45. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? Hazendonk HCAM; van Moort I; Mathôt RAA; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Blood Rev; 2018 Jul; 32(4):265-271. PubMed ID: 29426727 [TBL] [Abstract][Full Text] [Related]
46. A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusion. Zupančić-Šalek S; Vodanović M; Pulanić D; Skorić B; Matytsina I; Klovaite J Medicine (Baltimore); 2017 Dec; 96(52):e9075. PubMed ID: 29384900 [TBL] [Abstract][Full Text] [Related]
47. Viral safety of coagulation factor concentrates: memoirs from an insider. Mannucci PM J Thromb Haemost; 2018 Apr; 16(4):630-633. PubMed ID: 29383815 [TBL] [Abstract][Full Text] [Related]
48. Hemlibra's Remarkable Efficacy A Beacon For Hemophilia Patients. Morrow T Manag Care; 2018 Feb; 27(2):30-32. PubMed ID: 29451467 [TBL] [Abstract][Full Text] [Related]
49. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036 [TBL] [Abstract][Full Text] [Related]
50. World bleeding disorders registry: The pilot study. Coffin D; Herr C; O'Hara J; Diop S; Hollingsworth R; Srivastava A; Lillicrap D; van den Berg HM; Iorio A; Pierce GF Haemophilia; 2018 May; 24(3):e113-e116. PubMed ID: 29388721 [No Abstract] [Full Text] [Related]
51. The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia. De la Corte-Rodriguez H; Rodriguez-Merchan EC; Alvarez-Roman MT; Martin-Salces M; Martinoli C; Jimenez-Yuste V Expert Rev Hematol; 2018 Mar; 11(3):253-261. PubMed ID: 29383965 [TBL] [Abstract][Full Text] [Related]
52. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products. Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389 [TBL] [Abstract][Full Text] [Related]
54. Risk of major comorbidities among workers with hemophilia: A 14-year population-based study. Chu WM; Ho HE; Wang JD; Chan WC; Liou YS; Ho WC; Hu SY; Tsan YT Medicine (Baltimore); 2018 Feb; 97(6):e9803. PubMed ID: 29419677 [TBL] [Abstract][Full Text] [Related]
55. Hemophilia A: different phenotypes may be explained by multiple and variable effects of the causative mutation in the Castaman G Haematologica; 2018 Feb; 103(2):195-196. PubMed ID: 29386375 [No Abstract] [Full Text] [Related]
56. 11th Annual Congress of the European Association for Haemophilia and Allied Disorders 2018, 7-9 February 2018, Madrid, Spain. Haemophilia; 2018 Feb; 24 Suppl 1():5-135. PubMed ID: 29383804 [No Abstract] [Full Text] [Related]
57. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report. Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626 [TBL] [Abstract][Full Text] [Related]
58. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia. Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801 [TBL] [Abstract][Full Text] [Related]
59. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective. Miesbach W; Sawyer EK Hum Gene Ther Clin Dev; 2018 Jun; 29(2):80-89. PubMed ID: 29624465 [TBL] [Abstract][Full Text] [Related]